Paratek Pharmaceuticals
Paratek Pharmaceuticals develops transformative solutions for infectious diseases and other challenging conditions, with key products like NUZYRA and SEYSARA approved by the FDA.
Services
Paratek Pharmaceuticals is dedicated to developing transformative solutions for patients with infectious diseases and other difficult to treat conditions. A significant focus is on addressing antimicrobial resistance, a critical global public health issue. Through their comprehensive compliance programs, Paratek ensures adherence to ethical business practices and compliance with applicable laws, regulations, guidelines, and policies.
Products
Paratek Pharmaceuticals offers products like NUZYRA and SEYSARA. NUZYRA is an FDA-approved tetracycline-class antibiotic for adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. SEYSARA is FDA-approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years and older.
Partnerships and Collaborations
Paratek Pharmaceuticals holds worldwide rights to omadacycline and has a partnership for its development and commercialization in the Greater China region. Additionally, they have a broad-based Project BioShield contract with BARDA for studying NUZYRA against anthrax.
Locations
Paratek Pharmaceuticals operates from two primary locations in the United States. The company has offices in King of Prussia, Pennsylvania, and Boston, Massachusetts.